Global Research Syndicate
No Result
View All Result
  • Latest News
  • Consumer Research
  • Survey Research
  • Marketing Research
  • Industry Research
  • Data Collection
  • More
    • Data Analysis
    • Market Insights
  • Latest News
  • Consumer Research
  • Survey Research
  • Marketing Research
  • Industry Research
  • Data Collection
  • More
    • Data Analysis
    • Market Insights
No Result
View All Result
globalresearchsyndicate
No Result
View All Result
Home Data Analysis

Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice

globalresearchsyndicate by globalresearchsyndicate
January 13, 2021
in Data Analysis
0
Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

  • [1].

    Correlates of protection induced by vaccination.

    Clin Vaccine Immunol. 2010; 17: 1055-1065

  • [2].

    Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.

    J Virol. 2013; 87: 9939-9942

  • [3].
    • Wong SK
    • Li W
    • Moore MJ
    • Choe H
    • Farzan M.

    A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.

    J Biol Chem. 2004; 279: 3197-3201

  • [4].
    • Ni L
    • Ye F
    • Cheng ML
    • et al.

    Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.

    Immunity. 2020; 52 (): 971-977

  • [5].
    • Zhou D
    • Duyvesteyn HME
    • Chen CP
    • et al.

    Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.

    Nat Struct Mol Biol. 2020;

  • [6].
    • Rogers TF
    • Zhao F
    • Huang D
    • et al.

    Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.

    Science. 2020; 369: 956-963

  • [7].

    Potent Neutralizing Antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B Cells.

    Cell. 2020; 182 (): 73-84

  • [8].
    • Shi R
    • Shan C
    • Duan X
    • et al.

    A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.

    Nature. 2020; 584: 120-124

  • [9].
    • Grifoni A
    • Weiskopf D
    • Ramirez SI
    • et al.

    Targets of T Cell Responses to SARS-CoV-2 coronavirus in humans with COVID-19 Disease and Unexposed Individuals.

    Cell. 2020; 181 (): 1489-1501

  • [10].
    • Weiskopf D
    • Schmitz KS
    • Raadsen MP
    • et al.

    Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.

    Sci Immunol. 2020; 5

  • [11].
    • Kunzli M
    • Schreiner D
    • Pereboom TC
    • et al.

    Long-lived T follicular helper cells retain plasticity and help sustain humoral immunity.

    Sci Immunol. 2020; 5

  • [12].

    Revealing the role of CD4(+) T cells in viral immunity.

    J Exp Med. 2012; 209: 1391-1395

  • [13].
    • Jackson LA
    • Anderson EJ
    • Rouphael NG
    • et al.

    An mRNA Vaccine against SARS-CoV-2 – preliminary report.

    N Engl J Med. 2020;

  • [14].
    • Erasmus JH
    • Khandhar AP
    • O’Connor MA
    • et al.

    An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates.

    Sci Transl Med. 2020; 12

  • [15].
    • Yu J
    • Tostanoski LH
    • Peter L
    • et al.

    DNA vaccine protection against SARS-CoV-2 in rhesus macaques.

    Science. 2020;

  • [16].
    • Smith TRF
    • Patel A
    • Ramos S
    • et al.

    Immunogenicity of a DNA vaccine candidate for COVID-19.

    Nat Commun. 2020; 11: 2601

  • [17].
    • Zhu FC
    • Guan XH
    • Li YH
    • et al.

    Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.

    Lancet. 2020;

  • [18].
    • Corbett KS
    • Flynn B
    • Foulds KE
    • et al.

    Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.

    N Engl J Med. 2020;

  • [19].

    Development of an inactivated vaccine candidate for SARS-CoV-2.

    Science. 2020; 369: 77-81

  • [20].
    • Castilow EM
    • Olson MR
    • Varga SM.

    Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.

    Immunol Res. 2007; 39: 225-239

  • [21].
    • Tseng CT
    • Sbrana E
    • Iwata-Yoshikawa N
    • et al.

    Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.

    PLoS One. 2012; 7: e35421

  • [22].
    • Arvin AM
    • Fink K
    • Schmid MA
    • et al.

    A perspective on potential antibody-dependent enhancement of SARS-CoV-2.

    Nature. 2020; 584: 353-363

  • [23].
    • Keech C
    • Albert G
    • Cho I
    • et al.

    Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

    N Engl J Med. 2020;

  • [24].
    • Mandolesi M
    • Sheward DJ
    • Hanke L
    • et al.

    SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses.

    2020 ()

  • [25].
    • Del Giudice G
    • Rappuoli R
    • Didierlaurent AM.

    Correlates of adjuvanticity: a review on adjuvants in licensed vaccines.

    Semin Immunol. 2018;

  • [26].
    • Khurana S
    • Verma N
    • Yewdell JW
    • et al.

    MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

    Sci Transl Med. 2011; 3 ()

  • [27].
    • Hansen B
    • Sokolovska A
    • HogenEsch H
    • Hem SL.

    Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response.

    Vaccine. 2007; 25: 6618-6624

  • [28].
    • HogenEsch H
    • O’Hagan DT
    • Fox CB.

    Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.

    NPJ Vaccines. 2018; 3: 51

  • [29].
    • Moyer TJ
    • Kato Y
    • Abraham W
    • et al.

    Engineered immunogen binding to alum adjuvant enhances humoral immunity.

    Nat Med. 2020; 26: 430-440

  • [30].
    • Colaprico A
    • Senesi S
    • Ferlicca F
    • et al.

    Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation.

    Vaccine. 2020; 38: 3600-3609

  • [31].
    • Corbett KS
    • Edwards DK
    • Leist SR
    • et al.

    SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.

    Nature. 2020;

  • [32].
    • Wrapp D
    • Wang N
    • Corbett KS
    • et al.

    Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

    Science. 2020; 367: 1260-1263

  • [33].
    • Abraham S
    • Juel HB
    • Bang P
    • et al.

    Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

    Lancet Infect Dis. 2019; 19: 1091-1100

  • [34].
    • van Dissel JT
    • Joosten SA
    • Hoff ST
    • et al.

    A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.

    Vaccine. 2014; 32: 7098-7107

  • [35].
    • Davidsen J
    • Rosenkrands I
    • Christensen D
    • et al.

    Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6 ‘-dibehenate) – a novel adjuvant inducing both strong CMI and antibody responses.

    Bba-Biomembranes. 2005; 1718: 22-31

  • [36].
    • Knudsen NPH
    • Olsen A
    • Buonsanti C
    • et al.

    Different human vaccine adjuvants promote distinct antigenin-dependent immunological signatures tailored to different pathogens.

    Sci Rep-Uk. 2016; 6

  • [37].
    • Olsen AW
    • Follmann F
    • Erneholm K
    • Rosenkrands I
    • Andersen P.

    Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein.

    J Infect Dis. 2015; 212: 978-989

  • [38].
    • Sarzotti-Kelsoe M
    • Bailer RT
    • Turk E
    • et al.

    Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

    J Immunol Methods. 2014; 409: 131-146

  • [39].
    • Hanke L
    • Vidakovics Perez L
    • Sheward DJ
    • et al.

    An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.

    Nat Commun. 2020; 11: 4420

  • [40].

    Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.

    Trends Immunol. 2020; 41: 355-359

  • [41].

    Structures and distributions of SARS-CoV-2 spike proteins on intact virions.

    Nature. 2020;

  • [42].
    • Scheller C
    • Krebs F
    • Minkner R
    • Astner I
    • Gil-Moles M
    • Watzig H.

    Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.

    Electrophoresis. 2020; 41: 1137-1151

  • [43].
    • Organization World Health

    Expanded Programme on I. Manual for the production and control of vaccines: pertussis vaccine. Geneva:.

    1977 ()

  • [44].
    • Clapp T
    • Siebert P
    • Chen D
    • Jones Braun L

    Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

    J Pharm Sci. 2011; 100: 388-401

  • [45].
    • Lu F
    • Boutselis I
    • Borch RF
    • Hogenesch H.

    Control of antigen-binding to aluminum adjuvants and the immune response with a novel phosphonate linker.

    Vaccine. 2013; 31: 4362-4367

  • [46].
    • Hansen B
    • Belfast M
    • Soung G
    • et al.

    Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response.

    Vaccine. 2009; 27: 888-892

  • [47].
    • Tam HH
    • Melo MB
    • Kang M
    • et al.

    Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination.

    Proc Natl Acad Sci U S A. 2016; 113 ()

  • [48].
    • Kerfoot SM
    • Yaari G
    • Patel JR
    • et al.

    Germinal center B cell and T follicular helper cell development initiates in the interfollicular zone.

    Immunity. 2011; 34: 947-960

  • [49].
    • Pedersen GK
    • Worzner K
    • Andersen P
    • Christensen D.

    Vaccine adjuvants differentially affect kinetics of antibody and germinal center responses.

    Front Immunol. 2020; 11579761

  • [50].
    • Kim HW
    • Canchola JG
    • Brandt CD
    • et al.

    Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

    Am J Epidemiol. 1969; 89: 422-434

  • [51].
    • Honda-Okubo Y
    • Barnard D
    • Ong CH
    • Peng BH
    • Tseng CT
    • Petrovsky N.

    Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.

    J Virol. 2015; 89: 2995-3007

  • [52].

    Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.

    Elife. 2020; : 9

  • [53].
    • Rogers TF
    • Zhao F
    • Huang D
    • et al.

    Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.

    Science. 2020;

  • [54].
    • Swain SL
    • McKinstry KK
    • Strutt TM.

    Expanding roles for CD4(+) T cells in immunity to viruses.

    Nat Rev Immunol. 2012; 12: 136-148

  • [55].
    • Bolles M
    • Deming D
    • Long K
    • et al.

    A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

    J Virol. 2011; 85: 12201-12215

  • [56].
    • Snell LM
    • Osokine I
    • Yamada DH
    • De la Fuente JR
    • Elsaesser HJ
    • Brooks DG.

    Overcoming CD4 Th1 Cell Fate Restrictions to Sustain Antiviral CD8 T cells and control persistent virus infection.

    Cell Rep. 2016; 16: 3286-3296

  • [57].
    • Francica JR
    • Zak DE
    • Linde C
    • et al.

    Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

    Blood Adv. 2017; 1: 2329-2342

  • [58].
    • Khurana S
    • Verma N
    • Yewdell JW
    • et al.

    MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

    Sci Transl Med. 2011; 3

  • [59].
    • Boudreau CM
    • Yu WH
    • Suscovich TJ
    • Talbot HK
    • Edwards KM
    • Alter G.

    Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination.

    J Clin Invest. 2020; 130: 662-672

  • [60].
    • Pallesen J
    • Wang N
    • Corbett KS
    • et al.

    Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

    Proc Natl Acad Sci U S A. 2017; 114 ()

  • [61].
    • Wang X
    • Guo X
    • Xin Q
    • et al.

    Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients.

    Clin Infect Dis. 2020;

  • [62].

    Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

    Lancet Respir Med. 2020; 8: 420-422

  • [63].
    • Huang C
    • Wang Y
    • Li X
    • et al.

    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

    Lancet. 2020; 395: 497-506

  • [64].
    • Hotez PJ
    • Corry DB
    • Bottazzi ME.

    COVID-19 vaccine design: the Janus face of immune enhancement.

    Nat Rev Immunol. 2020; 20: 347-348

  • [65].
    • Pfeifle R
    • Rothe T
    • Ipseiz N
    • et al.

    Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease.

    Nat Immunol. 2017; 18: 104-113

  • Related Posts

    Understanding Variation In Nonurgent Pediatric Emergency Department Use In Communities With Concentrated Disadvantage
    Data Analysis

    An Employer-Provider Direct Payment Program Is Associated With Lower Episode Costs

    March 2, 2021
    Resource Use by Hospital Type for Frequent Inpatient Pediatric Conditions
    Data Analysis

    Resource Use by Hospital Type for Frequent Inpatient Pediatric Conditions

    March 2, 2021
    [Full text] Gait and Balance Disorder in Patients with Transient Ischemic Attack o
    Data Analysis

    [Full text] Increased Serum E-Selectin Levels Were Associated with Cognitive Decli

    March 2, 2021
    Understanding Variation In Nonurgent Pediatric Emergency Department Use In Communities With Concentrated Disadvantage
    Data Analysis

    The Affordable Care Act's Insurance Marketplace Subsidies Were Associated With Reduced Financial Burden For US Adults – healthaffairs.org

    March 2, 2021
    [Full text] Gait and Balance Disorder in Patients with Transient Ischemic Attack o
    Data Analysis

    [Full text] miR-621 May Suppress Cell Proliferation via Targeting lncRNA SNHG10 in

    March 1, 2021
    [Full text] Gait and Balance Disorder in Patients with Transient Ischemic Attack o
    Data Analysis

    [Full text] Factors Associated with Medication-Related Burden Quality of Life (MRB

    March 1, 2021
    Next Post

    Global Disposable Incontinence Products Market Strategic Assessment & SWOT Analysis 2021-2025

    Categories

    • Consumer Research
    • Data Analysis
    • Data Collection
    • Industry Research
    • Latest News
    • Market Insights
    • Marketing Research
    • Survey Research
    • Uncategorized

    Recent Posts

    • Leader wins Acronis distribution agreement, brings cyber protection solutions to Aus
    • An Employer-Provider Direct Payment Program Is Associated With Lower Episode Costs
    • Grease Market Size 2021 | Global Industry Share, Trends, Growth Insights, SWOT Analysis by Top Key Vendors and Forecast to 2027 – The Bisouv Network
    • Privacy Policy
    • Terms of Use
    • Antispam
    • DMCA
    • Contact Us

    Copyright © 2021 Globalresearchsyndicate.com

    No Result
    View All Result
    • Latest News
    • Consumer Research
    • Survey Research
    • Marketing Research
    • Industry Research
    • Data Collection
    • More
      • Data Analysis
      • Market Insights

    Copyright © 2021 Globalresearchsyndicate.com

    Login to your account below

    Forgotten Password?

    Fill the forms bellow to register

    All fields are required. Log In

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In